The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?
Open accessAbstract
Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and development. Most antileishmanial drugs are highly toxic, present resistance issues or require hospitalization, being therefore not adequate to the field. Recently improvements have been achieved by combination therapy, reducing the time and cost of treatment. Nonetheless, new drugs are still urgently needed. In this review, we describe the current visceral leishmaniasis (VL) treatments and their limitations. We also discuss the new strategies in the drug discovery field including the development and implementation of high-throughput screening (HTS) assays and the joint efforts of international teams to deliver clinical candidates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
The Genome of the Kinetoplastid Parasite, Leishmania major
Ivens, A. C., Peacock, C. S., Worthey, E. A., Murphy, L., Aggarwal, G., Berriman, M., Sisk, E., Rajandream, M.-A., Adlem, E., Aert, R., et al. (2005) · Science · doi:10.1126/science.1112680 · Cited by 1,346
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Comparative genomic analysis of three Leishmania species that cause diverse human disease
Peacock, C. S., Seeger, K., Harris, D., Murphy, L., Ruiz, J. C., Quail, M. A., Peters, N., Adlem, E., Tivey, A., Aslett, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2053 · Cited by 768
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Library, W. (2010) · Cited by 579
Innovative lead discovery strategies for tropical diseases
Nwaka, S., & Hudson, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2144 · Cited by 521
Cited by
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Metadata
- Authors
- Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L.
- Venue
- International Journal for Parasitology: Drugs and Drug Resistance
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 2
- Pages
- 11-19
- ISSN
- 2211-3207 (ISSN-L)
- OpenAlex
- W2145904172
- Cited by
- 294
- References
- 51
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? https://app.cochat.ai/papers/10.1016/j.ijpddr.2012.01.003
- The paper
- Freitas-Junior, L. H., Chatelain, E., Kim, H. A., & Siqueira-Neto, J. L. (2012). Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? International Journal for Parasitology: Drugs and Drug Resistance. https://doi.org/10.1016/j.ijpddr.2012.01.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
